ライフサイエンスコーパス: ABCB1

1 otein MDR1 (also known as P-glycoprotein and ABCB1).

2 he efflux transporter, P-glycoprotein (P-gp, ABCB1).

3 flux transporter P-glycoprotein (MDR1, P-gp, ABCB1).

4 he clinically relevant human P-glycoprotein (ABCB1).

5 ad low affinity toward P-glycoprotein (P-gp, ABCB1).

6 human counterpart, the MDR1 P-glycoprotein, ABCB1.

7 rane domains, TWD1 colocalizes with nonpolar ABCB1.

8 ghly homologous to the multidrug transporter ABCB1.

9 large cavity of the transmembrane region of ABCB1.

10 that activation of this pathway may restore ABCB1.

11 f ABCB1 and ABCG2, with a stronger effect on ABCB1.

12 s well as an ATP-dependent transporter gene, ABCB1.

13 howed a higher (3)H-IAA export activity than ABCB1.

14 ith the expression level and localization of ABCB1.

15 gene, encoding the multidrug resistance pump ABCB1.

16 ch broader range of cancer drugs effluxed by ABCB1.

17 Ko143, and they are selective for ABCG2 over ABCB1.

18 er in ABCB1 1236TT homozygotes compared with ABCB1 1236C carriers and was 12.4% higher in IL-10 -1082

19 ABCB1 1236C>T under the recessive model and IL-10 -1082G

20 Genotyping was performed for ABCB1 1236C>T, 2677 G>T/A, and 3435C>T; CYP3A4 -392A>G;

21 ate-binding cassette, subfamily B, member 1 (ABCB1) 1236C>T, 2677 G>T/A, and 3435C>T, cytochrome P450

22 Mean TG value was 25.1% higher in ABCB1 1236TT homozygotes compared with ABCB1 1236C carri

23 -Americans were twice as likely to carry the ABCB1 2677 G/G genotype (78.6% vs. 33.7%, P < 0.0025), a

24 For grade 4 neutropenia, the HR for ABCB1 3425C-->T was 1.84 (95% CI, 0.77 to 4.48; P = .19)

25 2) = 0.07, p = 1.9 x 10(-11)), whereas PON1, ABCB1 3435 C-->T, and other candidate SNPs were not.

26 Individuals with the ABCB1 3435 TT genotype have reduced platelet inhibition

27 er CYP2C19 reduced-function allele carriers, ABCB1 3435 TT homozygotes, or both were at increased ris

28 ABCB1 3435 was genotyped in 315 patients with epilepsy,

29 ABCB1 3435C>T and IL-10 -1082G>A were significantly asso

30 ABCB1 3435C>T and IL-10 -1082G>A were significantly asso

31 reviously showed significant associations of ABCB1 3435C>T and IL-10 -1082G>A with log-transformed SR

32 Under the dominant genetic model, ABCB1 3435C>T was associated with TC (P=0.0001) and LDL-

33 ABCB1 3435C-->T and CYP2C19 genotypes were significant,

34 We evaluated the association between ABCB1 3435C-->T and rates of the primary efficacy endpoi

35 We then assessed the combined effect of ABCB1 3435C-->T genotype and reduced-function alleles of

36 In patients treated with clopidogrel, ABCB1 3435C-->T genotype was significantly associated wi

37 The ABCB1 3435C-->T polymorphism and three-SNP haplotype, pl

38 There was no association of the ABCB1 3435C-->T polymorphism, the three-SNP haplotype, o

39 The ABCB1 3435C-->T single-nucleotide polymorphism (SNP) or

40 Mean SRL C/D was 48% higher in patients with ABCB1 3435CT/TT genotype than those with 3435CC genotype

41 26.9 and 24.9 mg/dL higher, respectively, in ABCB1 3435T carriers than 3435CC homozygotes at an avera

42 nor CC genotype at C3435T (rs1045642) within ABCB1, a variant known to alter protein expression, was

43 SLC22A7, SLC47A1, SLCO1B1, SLCO1B3, SLCO2B1, ABCB1, ABCB11, ABCC2, ABCC3, ABCC4, ABCC6, and ABCG2 We

44 Mutations in TWD1 caused mislocalization of ABCB1, ABCB4, and ABCB19 to the ER instead of the plasma

45 triphosphate-binding cassette transporters (ABCB1, ABCB4, and ABCC1) were present.

46 etic polymorphisms in CYP2B6, NR1I3, CYP2A6, ABCB1, ABCB5, and ABCG2.

47 These include ABCA2, ABCB1, ABCB6, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC10,

48 y influence cellular sensitivity to taxanes (ABCB1, ABCC1, ABCC2, ABCG2, CDKN1A, CYP1B1, CYP2C8, CYP3

49 s multidrug resistance (MDR) mediated by the ABCB1, ABCC1, and ABCG2 drug-efflux transporters.

50 cts on cell surface ABC transporters such as ABCB1, ABCC1, and ABCG2 that modulate intracompartmental

51 terization of new fluorescent substrates for ABCB1, ABCC1, and ABCG2.

52 Three ABC efflux transporters (ABCB1, ABCC3, and ABCB5) showed significant negative cor

53 ss response (cas8, 14-3-3epsilon, p-38 MAPK, Abcb1, Abcc5) was investigated.

54 We successfully implemented ABCB1/ABCG2 inhibition protocols in nonhuman primates re

55 ib (10 mg/kg) or after pretreatment with the ABCB1/ABCG2 inhibitor elacridar (10 mg/kg).

56 We assessed the efficacy of two different ABCB1/ABCG2 inhibitors to enhance brain distribution of

57 Pharmacologic strategies to inhibit ABCB1/ABCG2-mediated efflux transport at the BBB have be

58 ter via acetylation of histone H3 initiating ABCB1 activation, further elucidating the genetic and ep

59 ively characterized MDR transporters include ABCB1 (also known as MDR1 or P-glycoprotein) and ABCC1 (

60 is the overexpression of drug efflux pumps, ABCB1 (also known as MDR1 or P-gp) and ABCC1 (also known

61 The ABC transporter P-glycoprotein (Pgp; ABCB1) also contains a Pim-1 phosphorylation consensus s

62 ATP-binding cassette sub-family B member 1 (ABCB1, also known as MDR1 and P-glycoprotein 170).

63 ect to efflux via P-glycoprotein (encoded by ABCB1, also known as MDR1).

64 ased the expression of P-glycoprotein (P-gp, ABCB1), an ATP binding cassette that is usually associat

65 We expressed Arabidopsis ABCB1 and ABCB19 in mam1pdr1 host lines under the induci

66 romosomal region 7q21.12 harbouring both the ABCB1 and ABCB4 genes, with the most notable SNPs after

67 ing the potential functional significance of ABCB1 and ABCB4, underlines the likely importance of the

68 sed ATP-binding-cassette (ABC) transporters, ABCB1 and ABCB5.

69 to paclitaxel because of the upregulation of ABCB1 and ABCB5.

70 ce and transport were inhibited by the human ABCB1 and ABCC1 modulator verapamil.

71 stigations of the inhibitory activity toward ABCB1 and ABCC1 yielded a high selectivity toward ABCG2

72 gh activation of the multidrug transporters, Abcb1 and Abcc1, and through 5-lipoxygenase activity.

73 sed expression of ABCB5, along with enhanced ABCB1 and ABCC3 transcript expression.

74 asma membrane of CD44, the EGF receptor, the ABCB1 and ABCG2 drug transporters, and the MCT4 monocarb

75 ion level or the subcellular distribution of ABCB1 and ABCG2 in the cells exposed to 3 muM of bafetin

76 study was to investigate the effects of the ABCB1 and ABCG2 inhibitor elacridar on brain uptake usin

77 The inhibition of ABCB1 and ABCG2 is a promising approach to enhance brain

78 Transporters such as ABCB1 and ABCG2 limit the exposure of several anticancer

79 rst-trimester explants decreased (P < 0.001) ABCB1 and ABCG2 mRNA and protein levels.

80 Bafetinib significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their antica

81 When Abcb1 and Abcg2 were disrupted in mice, brain uptake of

82 gnificantly decreases the efflux activity of ABCB1 and ABCG2, but has no significant effects on ABCC1

83 denafil inhibits the transporter function of ABCB1 and ABCG2, with a stronger effect on ABCB1.

84 ct inhibition of the drug efflux function of ABCB1 and ABCG2.

85 tinib stimulated the ATPase activity of both ABCB1 and ABCG2.

86 obiliary excretion, which may be mediated by ABCB1 and ABCG2.

87 plus a comprehensive set of tag SNPs across ABCB1 and adjacent ABCB4, were genotyped in a cohort of

88 iated with lowered gene expression of ABCG2, ABCB1 and AKR1C1.

89 dergone percutaneous intervention, when both ABCB1 and CYP2C19 are taken into account, nearly half of

90 studies are necessary to define the role of ABCB1 and IL-10 polymorphisms on SRL-induced dyslipidemi

91 ells to prevent c-Jun-mediated expression of ABCB1 and maintain drug response.

92 ABCB1-, or ABCG2-overexpressing cells to non-ABCB1 and non-ABCG2 substrate drugs, nor did sildenafil

93 n19) transporter functions coordinately with ABCB1 and PIN1 to motivate long-distance transport of th

94 three recurrent mutated genes in OAC: TP53, ABCB1 and SEMA5A, not present in FLO-1 or OE33.

95 n and functional activity of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) effl

96 cause of efflux transport by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), the

97 s P-glycoprotein (P-gp, official gene symbol ABCB1) and breast cancer resistance protein (BCRP, offic

98 g the drug efflux pump P-glycoprotein (P-gp, ABCB1) and MRP1 (ABCC1).

99 P and screened against P-glycoprotein (P-gp, ABCB1) and multidrug resistance protein 1 (MRP1, ABCC1)

100 lopramide transport by P-glycoprotein (P-gp; ABCB1) and the breast cancer resistance protein (BCRP; A

101 ioid receptor (OPRM1), multidrug resistance (ABCB1), and catechol-o-methyltransferase (COMT) genes ar

102 Use of T cells deficient in 5-lipoxygenase, Abcb1, and Abcc1, and comparison of the effects of FTY72

103 ionships between 22 polymorphisms in CYP2B6, ABCB1, and CYP3A5; plasma efavirenz exposure; and/or tre

104 ABCG2, ABCB1, and possibly other transporters influence in vivo

105 ) and drug metabolism and transport (CYP3A5, ABCB1, and PXR) were analyzed in kidney transplant recip

106 KCNK2, LRP1B, NKX6-1, NOPE, PCDHGA12, RPIB9, ABCB1, and SLC2A14) identified as differentially methyla

107 our study indicated that bafetinib reversed ABCB1- and ABCG2-mediated MDR by blocking the drug efflu

108 Overall, we conclude that erlotinib reverses ABCB1- and ABCG2-mediated MDR in cancer cells through di

109 was found to have inhibitory effects on both ABCB1- and ABCG2-mediated MDR in this in-vitro investiga

110 hate-binding cassette subfamily B, member 1 [ABCB1]) and breast cancer resistance protein (adenosine

111 ymorphisms in CACNA1G, CACNA1H, CACNA1I, and ABCB1 are associated with differential short-term seizur

112 tment failure in DLBCL and identify GPX1 and ABCB1 as potentially powerful biomarkers of early failur

113 ry new drug is now screened for transport by ABCB1, as this limits oral availability and penetration

114 Bafetinib stimulated ABCB1 ATPase activities while inhibited ABCG2 ATPase act

115 igations revealed that sildenafil stimulated ABCB1 ATPase activity and inhibited photolabeling of ABC

116 bsequent research showed that Dw3 encodes an ABCB1 auxin transporter and Dw1 encodes a highly conserv

117 Candidate genes (TYMS, MTHFR, ABCB1, BGLAP, ACP5, LRP5, ESR1, PAI-1, VDR, PTH, and PTH

118 were resistant to paclitaxel, a substrate of ABCB1, both in vitro and in vivo.

119 Significantly lower expression of ABCB1 but not ABCC4 or ABCG2 was found following exposur

120 selectively blocking the efflux function of ABCB1, but not interfering with the expression level and

121 binding domains of sea urchin versus murine ABCB1 by mutation of Sp-ABCB1a and treatment of embryos

122 telet aggregation values were similar across ABCB1 C3435T genotypes (P=0.73).

123 ABCB1 C3435T genotypes did not influence the antiplatele

124 No significant influence of ABCB1 C3435T genotypes on the occurrence of ST was found

125 this study was to assess the association of ABCB1 C3435T genotypes with the antiplatelet efficacy of

126 Routine genotyping of ABCB1 C3435T polymorphisms should not be recommended for

127 ous coronary intervention were genotyped for ABCB1 C3435T, and ADP-induced platelet aggregation was a

128 PG analysis showed that ABCB1 (C3435T)T/T (membrane transport) was associated wi

129 taxel in P-gp-expressing SW620/Ad300 and HEK/ABCB1 cell lines.

130 We found no evidence that ABCB1 common variation influences either seizure or drug

131 ecause drug pumps like P-glycoprotein (P-gp, ABCB1) confer multidrug resistance and mutant ABC protei

132 human ATP-binding-cassette (ABC) transporter ABCB1, coupling of drug-binding by the two transmembrane

133 involved another 51 polymorphisms in CYP2B6, ABCB1, CYP3A4, and CYP3A5.

134 growth factor-beta1, Fas, FasL, granzyme B, ABCB1, CYP3A5.

135 lines, and they were not substrates for the ABCB1 drug efflux transporter.

136 carcinoma cell line known to overexpress the ABCB1 drug transporter and was also unaffected by overex

137 specific drugs by inducing expression of the ABCB1 drug transporter that prevents intracellular drug

138 The P-glycoprotein (P-gp, ABCB1) drug pump protects us from toxic compounds and co

139 a MDR1/A retrovirus overexpressing the human ABCB1 efflux pump (MDR cell line).

140 vity levels of the multidrug-resistance MDR1/ABCB1 encoded P- glycoprotein (P-gp) have an impact on t

141 believe that this may be attributed to MDR1/ABCB1 encoded P-gp mediating the efflux of immunosuppres

142 riants of CYP3A4, CYP3A5, CYP2C8, NR1I2-206, ABCB1, ERCC1, and ERCC2 were analyzed by pyrosequencing

143 he influence of the CYP3A4*22, CYP3A5*3, and ABCB1 exons 12, 21, and 26 polymorphisms in donors and r

144 ABCB1 expression correlated negatively with potencies of

145 th genetic and epigenetic susceptibility for ABCB1 expression in drug-resistant cells.

146 the pronounced species differences in ABCG2/ABCB1 expression ratios at the BBB.

147 amage responses, and to upregulate ABCG2 and ABCB1 expression, which therefore increased the cross-re

148 non of drug resistance, mediated by the MDR1/ABCB1 gene and seen in tumor cells to chemotherapeutic a

149 C3435T and G2677 polymorphisms of the MDR1/ABCB1 gene correlate with cellular expression levels of

150 The ABCB1 gene encodes P-glycoprotein, which limits brain co

151 The induction of ABCB1 gene expression is mediated by increased levels of

152 vity of the developed biosensor in detecting ABCB1 gene in genomic samples.

153 ses to SRL treatment, confirming the role of ABCB1 gene in SRL pharmacokinetics and pharmacodynamics.

154 We aimed to determine the effect of the ABCB1 gene on epilepsy drug response, using a unique lar

155 Similarly, testing of the ABCB1 gene only correctly foretold response in 51 (48.6%

156 Abcb1 gene resulted up-regulated at 48 hpf by PS-COOH wh

157 Complete activation of the ABCB1 gene through the coding region was proposed by int

158 G2677 and C3435T polymorphisms of the ABCB1 gene were determined by PCR in 170 heart transplan

159 entified in a DNA sequence mapping the human ABCB1 gene.

160 MDR1 (multidrug resistant-1), encoded by the ABCB1 gene.

161 hisms in the MDR1 (multidrug resistance 1 or ABCB1) gene involving frequent-to-rare codon substitutio

162 isorder predicts poor treatment outcome, but ABCB1 genetic effects in patients with cognitive impairm

163 The authors examined ABCB1 genetic variants as predictors of remission and si

164 ABCB1 genotypes were not significantly associated with c

165 , Madin-Darby canine kidney cells expressing ABCB1-GFP were used as a model to investigate this mutan

166 The functional SNP rs10245483 upstream from ABCB1 had a significant effect on remission and side eff

167 The P-glycoprotein (P-gp) drug pump (ABCB1) has two transmembrane domains and two nucleotide-

168 iants of the multidrug resistance gene (MDR1/ABCB1) have been associated with increased susceptibilit

169 We show that ABCB1-I541F is not properly folded and is more susceptib

170 plasma membrane expression, and activity of ABCB1-I541F.

171 We genotyped ABCB1 in 2932 patients with acute coronary syndromes und

172 transporter P-glycoprotein (P-gp) encoded by ABCB1 in human hepatoma cells (HepG2) without modifying

173 ansporters, BCRP (ABCG2) and P-glycoprotein (ABCB1), in the plasma membrane of human MPNST cells.

174 l genetic variant (C3435T, rs1045642) within ABCB1 influences clopidogrel treatment efficacy; however

175 etinal distribution volume VTResults: During ABCB1 inhibition, retinal VT and influx rate constant K1

176 d total retinal distribution volume VTDuring ABCB1 inhibition, retinal VT and influx rate constant K1

177 -verapamil distribution to the retina during ABCB1 inhibition, which provides first in vivo evidence

178 -verapamil distribution to the retina during ABCB1 inhibition, which provides first in vivo evidence

179 without and with concurrent infusion of the ABCB1 inhibitor tariquidar.

180 without and with concurrent infusion of the ABCB1 inhibitor tariquidar.

181 hermore, the strategy that co-administer MDR-ABCB1 inhibitor to overcome the resistance of one FDA ap

182 Ko143, gefitinib, and nilotinib, but not an ABCB1 inhibitor.

183 design and synthesis of a new generation of ABCB1 inhibitors, leading to further research on multidr

184 drug transport by human P-glycoprotein (Pgp, ABCB1) involves a coordinated communication between its

185 MDR1/ABCB1 is an interesting candidate gene for IBD.

186 P-glycoprotein (P-gp, ABCB1) is a member of the ATP-binding cassette (ABC) tra

187 P-glycoprotein (P-gp; ABCB1) is an ABC drug pump that protects us from toxic c

188 P-glycoprotein (P-gp, ABCB1) is an ATP-binding cassette drug pump that protect

189 The human P-glycoprotein (Pgp, ABCB1) is an ATP-dependent efflux pump for structurally

190 multidrug transporter P-glycoprotein (P-gp, ABCB1) is an ATP-dependent pump that mediates the efflux

191 bstrate specificity of human P-glycoprotein (ABCB1) is an essential feature of multidrug resistance.

192 P-glycoprotein (P-gp, ABCB1) is an important part of the multixenobiotic resis

193 P-glycoprotein (ABCB1) is expressed at the blood-retina barrier (BRB), w

194 CYP2C19, but not PON1 or ABCB1, is a significant determinant of the pharmacodynam

195 nce identity with the multidrug transporter, ABCB1, its N-terminal domain is poorly conserved, leadin

196 f CPT-11) AUC is explained by ABCC1 1684T>C, ABCB1 IVS9 -44A>G, and UGT1A1*93 (P = .004).

197 or of ABCC1 (MRP1), but not by inhibitors of ABCB1 (MDR-1, P-glycoprotein).

198 igenetic pathways that control the origin of ABCB1 (MDR1) gene activation with acquired multidrug res

199 ycoprotein (P-gp) 170 that is encoded by the ABCB1 (MDR1) gene.

200 ke the alternative MX transporters ABCG2 and ABCB1 (MDR1, P-glycoprotein)-can significantly influence

201 ms (SNPs) across five genes: CYP3A4, CYP3A5, ABCB1 (MDR1; encoding P-glycoprotein), NR1I2 (encoding t

202 In particular, ABCB1 [MDR1/P-glycoprotein (P-gp)] extrudes many types o

203 to valine mutation of human P-glycoprotein (ABCB1, MDR1) has been previously isolated from high colc

204 ively, we demonstrate that ABC transporters (ABCB1/MDR1 and ABCC2/MRP2, respectively) show dramatic o

205 the identity of germ-line variations in the ABCB1/MDR1 gene contributing to IBD susceptibility.

206 evidence to support the contribution of the ABCB1/MDR1 gene in determining risk to UC but not to CD

207 epresenting the haplotypic variations of the ABCB1/MDR1 gene were identified initially following the

208 administration of a TLR2 ligand, preserving ABCB1/MDR1 p-gp expression.

209 nduced synthesis and drug efflux activity of ABCB1/MDR1 p-gp in murine and human CD11b(+)-myeloid cel

210 biotic defense via the multidrug transporter ABCB1/MDR1 p-gp.

211 st a role for the multidrug resistance gene (ABCB1/MDR1) and its product, P-glycoprotein 170, in the

212 rase reporter gene assay and in decreases in ABCB1-mediated efflux of rhodamine 123.

213 TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [(3

214 hiazole-valine peptidomimetic, could reverse ABCB1-mediated MDR in vitro and in vivo.

215 tte (ABC) transporter, P-glycoprotein (P-gp; ABCB1), mediates the ATP-dependent efflux of a variety o

216 In lamotrigine subjects, 1 ABCB1 missense polymorphism (rs2032582/S893A; p = 0.015,

217 f MDR cells with 1 led to instability of the ABCB1 mRNA and consequently a reduction in P-gp protein,

218 Use of RNA interference reduced ABCB1 mRNA levels and concomitantly increased sensitivit

219 n of ABC transporters such as P-glycoprotein/ABCB1, MRP1/ABCC1, and MXR/ABCG2 seems to be a major cau

220 at the blood-brain barrier, P-glycoprotein (ABCB1), multidrug resistance associated protein 4 (ABCC4

221 embrane efflux pumps such as P-glycoprotein (ABCB1), multidrug resistance protein 1 (ABCC1), and brea

222 P-Glycoprotein (P-gp, ABCB1), multidrug resistance-associated protein 1 (MRP1,

223 esistant protein 1/P-glycoprotein (MDR1/Pgp; ABCB1), multidrug-resistant-associated protein 1 (MRP1;

224 er [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2)

225 nobiotic metabolism, including a decrease in ABCB1/multidrug resistance (MDR)1 p-glycoprotein (p-gp)

226 y potentiated the sensitivity of established ABCB1 or ABCG2 substrates and increased the accumulation

227 he I541F mutation, when reproduced either in ABCB1 or in ABCB4, led to retention in the endoplasmic r

228 t significantly alter the sensitivity of non-ABCB1 or non-ABCG2 substrates in all cells and was unabl

229 ssette family like the human P-glycoprotein (ABCB1 or Pgp) are responsible for many failed cancer and

230 ccumulation of paclitaxel or mitoxantrone in ABCB1- or ABCG2-overexpressing cells.

231 l did not alter the sensitivity of parental, ABCB1-, or ABCG2-overexpressing cells to non-ABCB1 and n

232 sed the accumulation of [(3)H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the e

233 cularly doxorubicin and [(3)H]-paclitaxel in ABCB1 overexpressing cells; mitoxantrone and [(3)H]-mito

234 s, thereby potently inhibiting the growth of ABCB1 overexpressing tumors.

235 In ABCB1-overexpressing cell lines, HG-829 significantly en

236 In ABCB1-overexpressing cells, nontoxic doses of sildenafil

237 Enhanced drug efflux mediated by ABCB1 P-glycoprotein and related ATP-binding cassette tr

238 the profound effect of the drug-transporting ABCB1 P-glycoprotein on the pharmacokinetics of drugs in

239 action demonstrated that lenalidomide was an ABCB1 (P-glycoprotein [P-gp]) substrate.

240 g docetaxel response, despite an increase in Abcb1 (P-glycoprotein) expression that was sufficient to

241 have shown recently that synonymous SNPs in ABCB1 (P-glycoprotein), which is implicated both in dete

242 pressed at high levels comparable to that of ABCB1 (P-glycoprotein).

243 in vitro data indicating lenalidomide was an ABCB1 (P-gp) substrate.

244 ulators of the membrane transporter proteins ABCB1 (P-gp), ABCG2 (BCRP), and ABCC1 (MRP1), which are

245 teins multi-drug resistance protein-1 (MDR1, ABCB1, P-glycoprotein) and (BCRP, ABCG2), and that targe

246 cassette (ABC) membrane transporters such as ABCB1/P-glycoprotein/MDR1 and ABCC1/MRP1 causes multidru

247 ers and to reverse ABC subfamily B member 1 (ABCB1; P-glycoprotein)- and ABC subfamily G member 2 (AB

248 G2/BCRP but not for the MDR1 P-glycoprotein (ABCB1/Pgp), multidrug resistance protein 1 (MRP1/ABCC1),

249 We examined the relationship between MDR1/ABCB1 polymorphisms and endomyocardial biopsy-proven rej

250 We assessed the association between ABCB1 polymorphisms and methadone dose requirements in 9

251 ABCB1 polymorphisms correlate with freedom from grade >

252 ABCB1 polymorphisms were found to be associated with lip

253 ABCB1 polymorphisms, particularly 3435C-->T, may affect

254 own disease, polymorphisms (CYP2C19, CYP3A5, ABCB1, PON1), noncompliance, co-medications, diet, smoki

255 ted in lower transcriptional activity of the ABCB1 promoter as judged from the luciferase reporter ge

256 Wnt3a reversed the Abeta-induced changes to ABCB1 protein.

257 anscription at a site 112 kb upstream of the ABCB1 proximal promoter (P1) in the drug-resistant cells

258 ans-alterations or epigenetic changes on the ABCB1 proximal promoter, which occurred during initial d

259 Cyclosporin A, a competitive substrate for ABCB1, restored maturation, plasma membrane expression,

260 induces MDR1 gene and P-glycoprotein (P-gp, ABCB1), resulting in a multidrug-resistant phenotype.

261 rodents, Abcg2) and P-glycoprotein (humans, ABCB1; rodents, Abcb1a/b) affects tissue distribution an

262 A decreased risk was found with ABCB1 rs1045642 (OR, 0.79; 95% CI, 0.71-0.89; FDR-P = 0.

263 sporters such as P-glycoprotein (P-gp; MDR1, ABCB1), significantly less is known regarding its intera

264 sociated with trough concentrations, and the ABCB1 single-nucleotide polymorphism rs4148738 and the C

265 The authors genotyped 10 ABCB1 single-nucleotide polymorphisms (SNPs) in 683 pati

266 Associations with the ABCB1 SNPs were not significant.

267 suggest a model of sequential engagement of Abcb1, SP1 receptors, 5-lipoxygenase, and Abcc1 to enhan

268 Methods: We performed PET scans with the ABCB1 substrate (R)-(11)C-verapamil on 5 healthy male vo

269 We performed PET scans with the ABCB1 substrate (R)-(11)C-verapamil on 5 healthy male vo

270 the effective intracellular concentration of ABCB1 substrate drugs such as paclitaxel.

271 elated negatively with potencies of 19 known ABCB1 substrates and with Baker's antifol and geldanamyc

272 sitivity to these two drugs, as expected for ABCB1 substrates.

273 nd penetration into sanctuaries protected by ABCB1, such as the brain.

274 Genetic variants in ABCB1, TGFB1, and XRCC1 appear to be associated with sus

275 e human multidrug resistance P-glycoprotein (ABCB1), the activity of which impairs the efficacy of ch

276 sequencing to assay mutations in CYP2C19 and ABCB1, the two genes genetically linked to respond.

277 rotein [multidrug resistance protein (MDR1); ABCB1], the in vivo effect on this and other transporter

278 In contrast, poly(I:C) decreased (P < 0.05) ABCB1, TLR-3, and TLR-4 mRNA levels in the third trimest

279 We found that the ability of ABCB1 to prevent accumulation of some drugs in the brain

280 rs that could identify tumors with increased Abcb1 transcript levels.

281 n, which provides first in vivo evidence for ABCB1 transport activity at the human BRB.

282 n, which provides first in vivo evidence for ABCB1 transport activity at the human BRB.

283 advantage of the gradual acquisition of the ABCB1 transporter during B cell maturation to delineate

284 : Four T-type calcium channel variants and 1 ABCB1 transporter variant were associated with different

285 the efflux of rhodamine 123 mediated by the ABCB1 transporter.

286 and evaluated a novel selective inhibitor of ABCB1 (TTT-28) with high efficacy and low toxicity.

287 used to verify specific ABC transporter B1 (ABCB1)-TWD1 interaction.

288 Remarkably, both ABCB1 upregulation and doxorubicin resistance caused by

289 that changes the chromatin structure of the ABCB1 upstream promoter via acetylation of histone H3 in

290 histone H3 within a 968-bp region 5' of the ABCB1 upstream promoter.

291 In conclusion, these data suggest that an ABCB1 variant known to alter protein expression represen

292 These data suggest that specific ABCB1 variants may have clinical relevance by influencin

293 ABCB1 variation has been associated with antidepressant

294 Finally, a reliable calibration curve of ABCB1 was obtained with an experimental detection limit

295 elapse SNPs, including variants in PDE4B and ABCB1, were also associated with antileukemic drug pharm

296 ansporter P-glycoprotein (Pgp; also known as ABCB1), which has a central role in the clearance of xen

297 the multidrug-resistance efflux transporter ABCB1, which is frequently expressed in resistant neurob

298 Pase activity and inhibited photolabeling of ABCB1 with [(125)I]-iodoarylazidoprazosin (IAAP), wherea

299 inib slightly inhibited the photolabeling of ABCB1 with [(125)I]iodoarylazidoprazosin (IAAP) at high

300 on of GPX1 and multidrug resistance 1 (MDR1; ABCB1) without early treatment failures and with superio